Matches in SemOpenAlex for { <https://semopenalex.org/work/W3024996947> ?p ?o ?g. }
- W3024996947 endingPage "66" @default.
- W3024996947 startingPage "56" @default.
- W3024996947 abstract "It has been more than 10 years since any new disease-modifying therapies have received regulatory approval for indications related to myelodysplastic syndromes (MDS). Advances in our collective biological understanding of MDS in the last decade, however, have made it possible to hope that effective therapeutics can be designed to improve MDS-associated cytopenias and patients' quality of life, and perhaps even delay clonal progression and extend survival. Classes of MDS-associated mutations and disordered biological pathways targeted by developmental therapeutics include the following: aberrant messenger RNA splicing, neomorphic enzymes in the citric acid cycle with oncogenic activity, overactivated tyrosine and serine-threonine kinases, epigenetic and chromatin remodeling alterations, abnormal telomere dynamics, and failed protection of DNA integrity. At present, treatments for MDS are usually administered as sequential monotherapy, but there is a trend toward clinical trials of combination therapies-in which new agents are added to a DNA hypomethylating agent backbone-for both upfront treatment and the treatment of relapsed/refractory disease. Agents in clinical trials for subsets of MDS include luspatercept, antibodies targeting CD33, isocitrate dehydrogenase inhibitors, deacetylase inhibitors, venetoclax, and immunotherapies designed to overcome immune checkpoint inhibition. These biologically based therapeutics, as well as the encouraging precedent of 7 new approvals by the US Food and Drug Administration in 2017 for the treatment of acute leukemia, offer the prospect that 10 more years will not elapse before another new therapy is approved for MDS." @default.
- W3024996947 created "2020-05-21" @default.
- W3024996947 creator A5009387581 @default.
- W3024996947 creator A5090527595 @default.
- W3024996947 date "2018-01-01" @default.
- W3024996947 modified "2023-10-18" @default.
- W3024996947 title "Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches." @default.
- W3024996947 cites W1499045657 @default.
- W3024996947 cites W1535095237 @default.
- W3024996947 cites W1602160610 @default.
- W3024996947 cites W1797862700 @default.
- W3024996947 cites W187238933 @default.
- W3024996947 cites W1889574318 @default.
- W3024996947 cites W1953890763 @default.
- W3024996947 cites W1965784693 @default.
- W3024996947 cites W1973707768 @default.
- W3024996947 cites W1976052439 @default.
- W3024996947 cites W1979144446 @default.
- W3024996947 cites W1979934252 @default.
- W3024996947 cites W1980954968 @default.
- W3024996947 cites W1984322159 @default.
- W3024996947 cites W1985823023 @default.
- W3024996947 cites W1986544757 @default.
- W3024996947 cites W1986987869 @default.
- W3024996947 cites W1993236149 @default.
- W3024996947 cites W1993524489 @default.
- W3024996947 cites W1994364791 @default.
- W3024996947 cites W1994881231 @default.
- W3024996947 cites W2000252768 @default.
- W3024996947 cites W2004089260 @default.
- W3024996947 cites W2009650262 @default.
- W3024996947 cites W2009854509 @default.
- W3024996947 cites W2016055354 @default.
- W3024996947 cites W2017468796 @default.
- W3024996947 cites W2021333892 @default.
- W3024996947 cites W2028919540 @default.
- W3024996947 cites W2030437009 @default.
- W3024996947 cites W2038248421 @default.
- W3024996947 cites W2040311067 @default.
- W3024996947 cites W2040852160 @default.
- W3024996947 cites W2041650481 @default.
- W3024996947 cites W2052890552 @default.
- W3024996947 cites W2060139171 @default.
- W3024996947 cites W2061595804 @default.
- W3024996947 cites W2065738117 @default.
- W3024996947 cites W2068160300 @default.
- W3024996947 cites W2070152906 @default.
- W3024996947 cites W2070433411 @default.
- W3024996947 cites W2074637790 @default.
- W3024996947 cites W2076367236 @default.
- W3024996947 cites W2077778517 @default.
- W3024996947 cites W2082710561 @default.
- W3024996947 cites W2084831115 @default.
- W3024996947 cites W2086974150 @default.
- W3024996947 cites W2091242855 @default.
- W3024996947 cites W2101892777 @default.
- W3024996947 cites W2103020543 @default.
- W3024996947 cites W2103336749 @default.
- W3024996947 cites W2106584820 @default.
- W3024996947 cites W2107398329 @default.
- W3024996947 cites W2113271378 @default.
- W3024996947 cites W2113736257 @default.
- W3024996947 cites W2114492363 @default.
- W3024996947 cites W2115528152 @default.
- W3024996947 cites W2118329428 @default.
- W3024996947 cites W2118771330 @default.
- W3024996947 cites W2126816979 @default.
- W3024996947 cites W2129580665 @default.
- W3024996947 cites W2133682816 @default.
- W3024996947 cites W2144892629 @default.
- W3024996947 cites W2146776050 @default.
- W3024996947 cites W2148968593 @default.
- W3024996947 cites W2149858388 @default.
- W3024996947 cites W2149982846 @default.
- W3024996947 cites W2150456410 @default.
- W3024996947 cites W2155296700 @default.
- W3024996947 cites W2156794452 @default.
- W3024996947 cites W2156954620 @default.
- W3024996947 cites W2157260351 @default.
- W3024996947 cites W2158104691 @default.
- W3024996947 cites W2166247867 @default.
- W3024996947 cites W2169007954 @default.
- W3024996947 cites W2170990953 @default.
- W3024996947 cites W2192207543 @default.
- W3024996947 cites W2294083716 @default.
- W3024996947 cites W2326726820 @default.
- W3024996947 cites W2339658711 @default.
- W3024996947 cites W2339828620 @default.
- W3024996947 cites W2346030347 @default.
- W3024996947 cites W2394724717 @default.
- W3024996947 cites W2463012969 @default.
- W3024996947 cites W2467917196 @default.
- W3024996947 cites W2549790759 @default.
- W3024996947 cites W2551607099 @default.
- W3024996947 cites W2560725920 @default.
- W3024996947 cites W2574794018 @default.
- W3024996947 cites W2587066646 @default.
- W3024996947 cites W2590030902 @default.